As of 5 Jul 2026, Neuland Lab share price is ₹18,944.00. The stock opened at ₹19,100.00, compared to its previous close of ₹18,988.00. During today's trading session, Neuland Lab share price moved in the range of ₹18,747.00 to ₹19,200.00, with an average price of ₹18,973.50 for the day. Looking at its last 52-week, the stock has touched a low of ₹11,500.00 and a high of ₹19,747.00. On the performance front, Neuland Lab share price has increased by 24.01% over the last six months and is up 62.36% on a year-on-year basis.
| Name | Mkt Cap Cr | P/E | P/B | ROE | D/E | ROCE | Book Value | Div. Yield | Turnover | EPS(TTM) |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries | 4,49,048.00 | 39.02 | 5.37 | 13.74% | 0.61 | 17.33% | 93.24 | 0.85% | 0.56 | 10.90 |
| Divis Laboratories | 1,77,179.00 | 69.00 | 10.57 | 15.32% | 0.00 | 19.56% | 629.49 | 0.45% | 0.58 | 98.19 |
| Torrent Pharmaceuticals | 1,57,804.00 | 66.03 | 17.03 | 26.76% | 1.05 | 18.30% | 16.90 | 0.90% | 0.49 | 64.75 |
| Cipla | 1,17,642.00 | 25.47 | 2.87 | 11.79% | 0.00 | 15.66% | 2.89 | 1.06% | 0.49 | 43.52 |
| Dr. Reddy's Laboratories | 1,12,368.00 | 27.03 | 2.97 | 11.07% | 0.18 | 12.54% | 375.78 | 0.59% | 0.63 | 38.68 |
| Zydus Lifesciences | 1,10,651.00 | 21.60 | 4.08 | 18.59% | 0.31 | 17.35% | 235.25 | 0.09% | 0.39 | 35.38 |
| Lupin | 1,09,676.00 | 20.48 | 4.89 | 23.76% | 0.04 | 24.88% | 659.05 | 0.75% | 0.61 | 129.18 |
| Mankind Pharma | 1,02,729.00 | 53.00 | 6.30 | 11.74% | 0.34 | 13.13% | 397.02 | 0.04% | 0.54 | 49.37 |
| Aurobindo Pharma | 90,608.00 | 25.87 | 2.39 | 9.25% | 0.19 | 11.76% | 391.14 | 0.26% | 0.48 | 41.58 |
| Laurus Labs | 82,398.90 | 60.26 | 10.10 | 18.21% | 0.45 | 16.70% | 10.19 | 0.20% | 0.97 | 13.72 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,476.84 | ₹1,558.58 | ₹1,191.20 | ₹951.08 |
| Other Income | ₹20.51 | ₹12.54 | ₹9.75 | ₹2.08 |
| Total Revenue | ₹1,497.35 | ₹1,571.12 | ₹1,200.95 | ₹953.15 |
| Total Expenses | ₹1,227.42 | ₹1,169.69 | ₹985.20 | ₹870.99 |
| Profit Before Tax | ₹346.33 | ₹401.44 | ₹215.75 | ₹82.16 |
| Tax | ₹86.22 | ₹101.36 | ₹52.23 | ₹18.34 |
| Profit After Tax | ₹260.11 | ₹300.08 | ₹163.52 | ₹63.82 |
| EPS - Basic | ₹202.74 | ₹233.89 | ₹127.45 | ₹49.74 |
| EPS - Diluted | ₹202.74 | ₹233.89 | ₹127.45 | ₹49.74 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹346.33 | ₹401.44 | ₹215.75 | ₹82.16 |
| Income before WC changes | ₹334.32 | ₹463.51 | ₹293.67 | ₹148.47 |
| Change in Assets | ₹28.58 | -₹99.00 | -₹153.28 | -₹17.75 |
| Change in Liabilities | ₹29.21 | ₹8.27 | ₹140.45 | -₹49.83 |
| Change in WC | ₹57.78 | -₹90.73 | -₹12.83 | -₹67.58 |
| Cash flow from Operations | ₹317.38 | ₹261.18 | ₹237.21 | ₹60.39 |
| Cash flow from Investing | -₹298.16 | -₹149.69 | -₹61.50 | -₹95.52 |
| Cash flow from Financing | ₹24.96 | -₹69.28 | -₹135.80 | ₹37.72 |
| Total Cash Flow | ₹44.19 | ₹42.21 | ₹39.92 | ₹2.59 |
| Cash (Start of the year) | ₹87.58 | ₹45.42 | ₹5.09 | ₹2.44 |
| Cash (End of the year) | ₹131.93 | ₹87.58 | ₹45.42 | ₹5.09 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹1,040.38 | ₹911.48 | ₹818.87 | ₹802.70 |
| Current Assets | ₹1,139.50 | ₹921.08 | ₹760.89 | ₹580.79 |
| Total Assets | ₹2,179.88 | ₹1,832.56 | ₹1,579.76 | ₹1,383.49 |
| Current Liabilities | ₹465.69 | ₹427.68 | ₹438.96 | ₹363.16 |
| Net Current Asset | ₹673.81 | ₹493.40 | ₹321.94 | ₹217.64 |
| Non-Current Liabilities | ₹189.39 | ₹122.17 | ₹146.71 | ₹179.83 |
| Equity Capital | ₹1,524.81 | ₹1,282.70 | ₹994.10 | ₹840.50 |
| Total Equity & Liabilities | ₹2,179.88 | ₹1,832.56 | ₹1,579.76 | ₹1,383.49 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Revenue | ₹1,476.84 | ₹1,558.58 | ₹1,191.20 | ₹951.08 |
| Other Income | ₹20.51 | ₹12.54 | ₹9.75 | ₹2.08 |
| Total Revenue | ₹1,497.35 | ₹1,571.12 | ₹1,200.95 | ₹953.15 |
| Total Expenses | ₹1,228.38 | ₹1,170.36 | ₹985.73 | ₹871.41 |
| Profit Before Tax | ₹345.37 | ₹400.77 | ₹215.21 | ₹81.74 |
| Tax | ₹85.95 | ₹101.17 | ₹52.09 | ₹18.21 |
| Profit After Tax | ₹259.43 | ₹299.60 | ₹163.12 | ₹63.53 |
| EPS - Basic | ₹202.20 | ₹233.51 | ₹127.14 | ₹49.52 |
| EPS - Diluted | ₹202.20 | ₹233.51 | ₹127.14 | ₹49.52 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Profit before tax | ₹345.37 | ₹400.77 | ₹215.21 | ₹81.74 |
| Income before WC changes | ₹333.36 | ₹462.84 | ₹293.14 | ₹147.92 |
| Change in Assets | ₹28.60 | -₹98.86 | -₹153.35 | -₹17.68 |
| Change in Liabilities | ₹30.15 | ₹7.64 | ₹142.31 | -₹49.31 |
| Change in WC | ₹58.75 | -₹91.22 | -₹11.04 | -₹66.99 |
| Cash flow from Operations | ₹317.49 | ₹260.06 | ₹238.53 | ₹60.41 |
| Cash flow from Investing | -₹298.14 | -₹149.67 | -₹61.50 | -₹95.53 |
| Cash flow from Financing | ₹24.96 | -₹69.28 | -₹135.80 | ₹37.72 |
| Total Cash Flow | ₹44.31 | ₹41.11 | ₹41.24 | ₹2.60 |
| Cash (Start of the year) | ₹86.07 | ₹44.96 | ₹3.72 | ₹1.12 |
| Cash (End of the year) | ₹130.38 | ₹86.07 | ₹44.96 | ₹3.72 |
| Particulars | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|
| Non-Current Assets | ₹1,040.35 | ₹911.46 | ₹819.00 | ₹802.87 |
| Current Assets | ₹1,137.82 | ₹919.47 | ₹760.34 | ₹579.25 |
| Total Assets | ₹2,178.17 | ₹1,830.93 | ₹1,579.34 | ₹1,382.12 |
| Current Liabilities | ₹472.84 | ₹433.80 | ₹445.75 | ₹368.13 |
| Net Current Asset | ₹664.98 | ₹485.67 | ₹314.59 | ₹211.12 |
| Non-Current Liabilities | ₹187.54 | ₹120.59 | ₹145.22 | ₹178.42 |
| Equity Capital | ₹1,517.79 | ₹1,276.54 | ₹988.36 | ₹835.57 |
| Total Equity & Liabilities | ₹2,178.17 | ₹1,830.93 | ₹1,579.34 | ₹1,382.12 |
Neuland Laboratories Ltd. is a global provider of active pharmaceutical ingredients (APIs) contract development and manufacturing organization (CDMO) services. It is focused on manufacture and sale of active pharmaceutical ingredients and allied services. It supports biotechnology and pharmaceutical companies in the design, development and manufacturing of complex APIs. It has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). It develops and manufactures non-exclusive APIs both Prime APIs comprising large volume, mature molecules, and specialty APIs comprising lower volume, complex molecules with less competition. It develops small molecules and peptides for clinical trials and beyond. It provides an end-to-end continuum of customized services from early-stage drug development (Pre-IND) through to commercial manufacturing of complex APIs, including process development, process optimization, analytical testing, and regulatory support.
Neuland Lab share price is ₹18,944.00 as on 03 Jul, 2026, 15:40 IST.
In the last 1 year, Neuland Lab delivered a return of 62.36%. The Neuland Lab share price hit a high of ₹19,747.00 and low of ₹11,500.00.
The Mutual Fund Shareholding in Neuland Lab was 11.35% at the end of Mar 2026.
The 52-week high and low of Neuland Lab share is ₹19,747.00 and ₹11,500.00 as of 03 Jul, 2026.
The market capitalisation of Neuland Lab is ₹24,354.10 Crores as on 03 Jul, 2026.
The stock symbol of Neuland Lab is NEULANDLAB on the NSE, 524558 on the BSE, and the ISIN is INE794A01010.
Neuland Lab shares closed yesterday at ₹18,988.00 on NSE & ₹18,982.30 on BSE
To buy Neuland Lab shares, open a demat account with Upstox and complete the KYC process. Once your account is set up, search for the stock and place your order.
No, shares of Neuland Lab or any other publicly traded company cannot be bought or sold on holidays when the stock exchanges are closed. You can only buy or sell Neuland Lab shares on days when the stock exchanges are open for trading. It's important to check the NSE & BSE holidays calendar, before placing any trades to avoid any inconvenience.
The PE and PB ratio of Neuland Lab is 66.91 and 13 respectively, as on 03 Jul, 2026, 15:40 IST.